Proficiency testing results for catecholamines
| Variable | Year | Trial | Specimen no. | No. | Mean±standard deviation | Coefficient of variation (%) | Median | Minimum | Maximum |
|---|---|---|---|---|---|---|---|---|---|
| Catecholamines, plasma (pg/mL) | |||||||||
| Dopamine | 2016 | 1st | CMCP-16-01 | 7 | 800.4±361.7 | 45.2 | 709.8 | 465.5 | 1,510.7 |
| CMCP-16-02 | 50.3±34.4 | 68.3 | 42.5 | 10.0 | 104.8 | ||||
| CMCP-16-03 | 300.3±78.9 | 26.3 | 285.8 | 196.2 | 401.9 | ||||
| 2nd | CMCP-16-04 | 7 | 39.3±21.1 | 53.7 | 41.4 | 10.0 | 71.1 | ||
| CMCP-16-05 | 273.2±19.1 | 7.0 | 273.7 | 251.7 | 305.6 | ||||
| CMCP-16-06 | 471.4±67.6 | 14.3 | 461.9 | 395.7 | 556.8 | ||||
| 2017 | 1st | CMCP-17-01 | 6 | 413.1±67.4 | 16.3 | 386.4 | 361.6 | 545.6 | |
| CMCP-17-02 | 383.5±114.9 | 30.0 | 426.1 | 156.7 | 456.7 | ||||
| CMCP-17-03 | 74.9±18.6 | 24.9 | 68.4 | 62.7 | 111.1 | ||||
| 2nd | CMCP-17-04 | 6 | 92.3±12.6 | 13.6 | 92.5 | 73.0 | 110.6 | ||
| CMCP-17-05 | 445.5±110.8 | 24.9 | 402.7 | 334.4 | 620.8 | ||||
| CMCP-17-06 | 433.7±130.7 | 30.1 | 453.7 | 209.0 | 609.8 | ||||
| Epinephrine | 2016 | 1st | CMCP-16-01 | 7 | 400.3±68.9 | 17.2 | 423.7 | 261.7 | 475.7 |
| CMCP-16-02 | 42.0±14.5 | 34.6 | 43.6 | 22.7 | 66.1 | ||||
| CMCP-16-03 | 181.9±12.4 | 6.8 | 185.3 | 158.1 | 197.1 | ||||
| 2nd | CMCP-16-04 | 7 | 49.7±14.4 | 28.9 | 51.6 | 27.8 | 63.8 | ||
| CMCP-16-05 | 232.5±33.7 | 14.5 | 228.2 | 195.0 | 280.8 | ||||
| CMCP-16-06 | 289.9±46.1 | 15.9 | 298.6 | 232.5 | 362.5 | ||||
| 2017 | 1st | CMCP-17-01 | 7 | 1116.5±99.5 | 8.9 | 1,145.9 | 923.1 | 1,211.6 | |
| CMCP-17-02 | 291.2±90.7 | 31.2 | 272.5 | 201.8 | 485.8 | ||||
| CMCP-17-03 | 73.8±12.7 | 17.2 | 72.6 | 58.2 | 92.6 | ||||
| 2nd | CMCP-17-04 | 7 | 56.3±8.1 | 14.5 | 59.4 | 42.2 | 66.2 | ||
| CMCP-17-05 | 1088.4±122.9 | 11.3 | 1,073.2 | 954.7 | 1,238.9 | ||||
| CMCP-17-06 | 314.3±117.3 | 37.3 | 272.9 | 238.2 | 550.0 | ||||
| Norepinephrine | 2016 | 1st | CMCP-16-01 | 7 | 1772.7±392.0 | 22.1 | 1,637.0 | 1,325.8 | 2,570.4 |
| CMCP-16-02 | 142.3±7.7 | 5.4 | 145.8 | 127.4 | 149.5 | ||||
| CMCP-16-03 | 754.8±141.9 | 18.8 | 744.7 | 586.6 | 1,021.4 | ||||
| 2nd | CMCP-16-04 | 7 | 179.5±50.0 | 27.8 | 168.6 | 133.0 | 265.9 | ||
| CMCP-16-05 | 898.3±147.8 | 16.5 | 940.2 | 696.0 | 1,087.5 | ||||
| CMCP-16-06 | 1086.4±141.5 | 13.0 | 1,106.4 | 904.3 | 1,319.3 | ||||
| 2017 | 1st | CMCP-17-01 | 7 | 1279.0±52.4 | 4.1 | 1,271.0 | 1,201.7 | 1,347.1 | |
| CMCP-17-02 | 962.6±190.8 | 19.8 | 1,068.7 | 616.7 | 1,109.8 | ||||
| CMCP-17-03 | 267.3±23.8 | 8.9 | 269.9 | 229.4 | 307.7 | ||||
| 2nd | CMCP-17-04 | 7 | 230.8±24.1 | 10.4 | 224.9 | 193.6 | 263.0 | ||
| CMCP-17-05 | 1272.4±82.2 | 6.5 | 1,265.1 | 1,167.2 | 1,395.7 | ||||
| CMCP-17-06 | 1040.8±53.0 | 5.1 | 1,054.6 | 944.0 | 1,097.2 | ||||
| Catecholamines, urine (ng/mL) | |||||||||
| Dopamine | 2016 | 1st | CMU-16-01 | 7 | 502.7±28.4 | 5.6 | 492.4 | 469.3 | 548.5 |
| CMU-16-02 | 93.6±8.0 | 8.5 | 90.7 | 85.4 | 108.5 | ||||
| CMU-16-03 | 504.0±37.5 | 7.4 | 483.8 | 463.9 | 563.1 | ||||
| 2nd | CMU-16-04 | 7 | 86.1±11.0 | 12.8 | 87.6 | 69.5 | 105.0 | ||
| CMU-16-05 | 490.7±33.5 | 6.8 | 498.8 | 447.0 | 540.5 | ||||
| CMU-16-06 | 493.4±36.4 | 7.4 | 504.1 | 445.2 | 547.6 | ||||
| 2017 | 1st | CMU-17-01 | 7 | 123.3±18.4 | 14.9 | 128.8 | 91.5 | 141.4 | |
| CMU-17-02 | 501.3±56.1 | 11.2 | 494.5 | 416.0 | 575.2 | ||||
| CMU-17-03 | 348.2±38.4 | 11.0 | 348.6 | 283.3 | 391.3 | ||||
| 2nd | CMU-17-04 | 7 | 460.6±32.1 | 7.0 | 454.0 | 427.0 | 512.6 | ||
| CMU-17-05 | 483.5±48.8 | 10.1 | 476.9 | 396.3 | 549.7 | ||||
| CMU-17-06 | 87.2±7.7 | 8.9 | 88.6 | 75.4 | 100.3 | ||||
| Epinephrine | 2016 | 1st | CMU-16-01 | 7 | 88.1±8.9 | 10.1 | 88.9 | 74.9 | 100.8 |
| CMU-16-02 | 14.0±1.9 | 13.9 | 13.9 | 11.7 | 17.4 | ||||
| CMU-16-03 | 85.5±6.6 | 7.7 | 86.1 | 74.0 | 92.1 | ||||
| 2nd | CMU-16-04 | 7 | 15.8±2.6 | 16.2 | 14.7 | 13.7 | 20.9 | ||
| CMU-16-05 | 91.0±17.1 | 18.8 | 86.2 | 68.8 | 123.9 | ||||
| CMU-16-06 | 90.8±14.2 | 15.6 | 87.1 | 70.9 | 116.2 | ||||
| 2017 | 1st | CMU-17-01 | 7 | 12.6±2.9 | 23.5 | 11.9 | 8.7 | 15.8 | |
| CMU-17-02 | 83.8±13.3 | 15.9 | 86.6 | 64.8 | 101.0 | ||||
| CMU-17-03 | 62.0±9.9 | 16.0 | 65.6 | 49.1 | 75.4 | ||||
| 2nd | CMU-17-04 | 7 | 87.3±13.9 | 15.9 | 84.4 | 74.4 | 116.3 | ||
| CMU-17-05 | 85.6±17.5 | 20.4 | 83.7 | 61.9 | 120.3 | ||||
| CMU-17-06 | 14.6±1.9 | 13.0 | 14.9 | 10.9 | 17.0 | ||||
| Norepinephrine | 2016 | 1st | CMU-16-01 | 7 | 201.2±8.0 | 4.0 | 198.8 | 188.4 | 213.1 |
| CMU-16-02 | 46.1±1.4 | 2.9 | 46.4 | 43.4 | 47.4 | ||||
| CMU-16-03 | 202.0±12.3 | 6.1 | 201.4 | 179.5 | 215.6 | ||||
| 2nd | CMU-16-04 | 7 | 46.9±2.9 | 6.2 | 46.0 | 44.1 | 51.9 | ||
| CMU-16-05 | 200.4±6.1 | 3.1 | 198.7 | 193.4 | 212.1 | ||||
| CMU-16-06 | 202.0±10.1 | 5.0 | 197.7 | 194.3 | 222.3 | ||||
| 2017 | 1st | CMU-17-01 | 7 | 43.8±4.5 | 10.2 | 44.4 | 37.0 | 49.9 | |
| CMU-17-02 | 191.0±16.6 | 8.7 | 199.6 | 162.1 | 206.3 | ||||
| CMU-17-03 | 180.4±14.6 | 8.1 | 187.5 | 159.1 | 195.3 | ||||
| 2nd | CMU-17-04 | 7 | 182.3±14.6 | 8.0 | 180.6 | 163.4 | 207.3 | ||
| CMU-17-05 | 189.4±14.3 | 7.6 | 186.7 | 169.4 | 212.3 | ||||
| CMU-17-06 | 47.3±2.4 | 5.1 | 46.4 | 44.8 | c |